<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: We evaluated the impact of remission of nephrotic-range <z:mp ids='MP_0002871'>albuminuria</z:mp> (&gt;2500 mg/24 h) (NRA) on <z:hpo ids='HP_0003774'>end-stage renal disease</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESRD</z:e>) and mortality in type 2 diabetic patients with <z:hpo ids='HP_0000112'>nephropathy</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: This was a follow-up observational study involving <z:hpo ids='HP_0000001'>all</z:hpo> 79 patients (35%; 62 men, 17 women) with NRA from a cohort of type 2 diabetic patients with <z:hpo ids='HP_0000112'>nephropathy</z:hpo> that was followed for at least 3 years at the Steno <z:mp ids='MP_0002055'>Diabetes</z:mp> Center (n=227) </plain></SENT>
<SENT sid="2" pm="."><plain>Patients were followed from the <z:hpo ids='HP_0003674'>onset</z:hpo> of NRA until <z:hpo ids='HP_0011420'>death</z:hpo> or January 2005 </plain></SENT>
<SENT sid="3" pm="."><plain>The mean age (+/-SD) was 60+/-8 years and known <z:mp ids='MP_0002055'>diabetes</z:mp> duration was 14+/-7 years </plain></SENT>
<SENT sid="4" pm="."><plain>Remission of NRA was defined as sustained <z:mp ids='MP_0002871'>albuminuria</z:mp> &lt;600 mg/24 h for at least 1 year </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: The duration of follow-up after <z:hpo ids='HP_0003674'>onset</z:hpo> of NRA was 6.5 years (range 2-20 years) </plain></SENT>
<SENT sid="6" pm="."><plain>Remission was induced in 20 (25%) of the patients, <z:hpo ids='HP_0000001'>all</z:hpo> treated with <z:chebi fb="2" ids="35457">ACE inhibitors</z:chebi> or <z:chebi fb="0" ids="2719,48432">angiotensin-II</z:chebi> receptor blockers </plain></SENT>
<SENT sid="7" pm="."><plain>Remission lasted 4.1 years (range 1-10 years) and only three patients relapsed </plain></SENT>
<SENT sid="8" pm="."><plain>At the end of follow-up, only 30% (two <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESRD</z:e> and four <z:hpo ids='HP_0011420'>deaths</z:hpo>) of the 20 patients with remission had reached the composite endpoint of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESRD</z:e> or <z:hpo ids='HP_0011420'>death</z:hpo>, in contrast to 66% (16 ESRD and 23 <z:hpo ids='HP_0011420'>deaths</z:hpo>) of the 59 patients without remission (p&lt;0.01) </plain></SENT>
<SENT sid="9" pm="."><plain>Cox regression analysis revealed that remission was associated with a risk reduction of 67% (95% CI 10-87) for reaching the composite endpoint of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESRD</z:e> or <z:hpo ids='HP_0011420'>death</z:hpo> and of 69% (95% CI 21-88%) for <z:hpo ids='HP_0011420'>death</z:hpo> alone </plain></SENT>
<SENT sid="10" pm="."><plain>Male sex, greater age and systolic blood pressure at <z:hpo ids='HP_0003674'>onset</z:hpo> of NRA were also independently associated with an increased risk of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESRD</z:e> and <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS/INTERPRETATION: Aggressive <z:chebi fb="0" ids="35674">antihypertensive</z:chebi> treatment can lead to long-term remission of NRA in a sizeable proportion of patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="12" pm="."><plain>Such remission is associated with a slower progression of <z:hpo ids='HP_0000112'>nephropathy</z:hpo> and substantially improved survival </plain></SENT>
</text></document>